Skip to main content
. 2018 May 21;14(6):1271–1280. doi: 10.5114/aoms.2018.73398

Figure 2.

Figure 2

Diagrams presenting: A – the difference between the percentage of CD3+/CD200+ lymphocytes in gastric cancer (GC) patients and healthy controls (***p < 0.00013 vs. control); B – the difference between the percentage of CD3+/CD200R+ lymphocytes in GC patients and healthy controls (***p < 0.0009 vs. control)